All In Biotech

Drug Trial Radar · NCT02684708

Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

European Network-Paediatric Hodgkin Lymphoma Study Group (EuroNet-PHL) Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

Last checked: Nov 19, 2026Latest source record: Mar 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 2,921 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

2,921

Actual

Start

Oct 1, 2015

Primary completion

Oct 31, 2024

Study completion Oct 31, 2025

Sponsor

Lead sponsor
University of GiessenAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Deutsche Krebshilfe e.V., Bonn (Germany); Euronet Worldwide
First posted
Feb 18, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, up to 25 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The EuroNet-PHL-C2 trial is an international, multicentre, randomised controlled trial with the aims to reduce the indication for radiotherapy in newly diagnosed patients with classical Hodgkin lymphoma without compromising cure rates and to investigate a chemotherapy intensification randomisation in intermediate and advanced classical Hodgkin lymphoma to compensate for reduction in radiotherapy.

Conditions

  • Classical Hodgkin Lymphoma

Interventions

  • cyclophosphamide, vincristine, prednisone, dacarbazineDrug

    28-day chemotherapy cycle

  • cyclo, vcr, pred, dacarb,etop and doxoDrug

    21-day chemotherapy cycle

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Event-free survivalTime frame: 5 years

Locations

19 sites in 19 countries. Site status is shown where the registry gives one.

  • Royal Children's Hospital and Monash Medical Centre Royal Children's Hospital

    Victoria Park, Australia

  • St. Anna Kinderspital

    Vienna, Austria

  • Paediatric haemato-oncology, University Hospitals of Leuven

    Leuven, Belgium

  • Dpt. of Pediatric Hematology and Oncology, Faculty Hospital Motol

    Prague, Czechia

  • Department of Pediatric Hematology/Oncology (5054) The Child and Youth Clinic, University Hospital of Copenhagen

    Copenhagen, Denmark

  • Service d'Oncohématologie, Hopital d'Ènfants Armand Trousseau

    Paris, France

  • Justus Liebig University of Giessen

    Giessen, Germany

  • Our Lady's Children's Hospital, Crumlin

    Dublin, Ireland

  • Tel Aviv University Schneider Children's Medical Center of Israel The Rina Zaizov Pediatric Hematology Oncology Division

    Petah Tikva, Israel

  • Pediatric Radiotherapy and Youth Area Unit C.R.O. - Centro di Riferimento Oncologico IRCCS

    Aviano, Italy

  • Princess Máxima Center for pediatric oncology

    Utrecht, Netherlands

  • Starship Blood and Cancer Centre, Starship Children's Hospital

    Auckland, New Zealand

  • Department of Medical Oncology Oslo University Hospital

    Oslo, Norway

  • Head of Department of Pediatric Oncology and Hematology, Polish-American Pediatric Institute, Jagiellonian University Medical Faculty

    Krakow, Poland

  • Clinic of Pediatric Oncology University Children's Hospital

    Bratislava, Slovakia

  • Sección de Onco-Hematología Pediátrica Hospital Universitario Virgen Macarena y Virgen del Rocío

    Seville, Spain

  • Pediatric Hematology & Oncology Children´s University Hospital

    Uppsala, Sweden

  • CHUV - Centre Hospitalier Universitaire Vaudois = LS, Départment femme - meré - enfant, Service de pédiatrie, Unité d'hématologie-oncologie pédiatrique

    Lausanne, Switzerland

  • University College London Hospitals

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.